Category: Multiple Sclerosis

Kesimpta®▼(ofatumumab): No increased risk of severe COVID-19 infections for adults with RRMS

•    Novartis announces that the peer-reviewed journal Neurology and Therapy1 has published new data on COVID-19 infections in people living with relapsing remitting multiple sclerosis (RRMS) treated with Kesimpta® (ofatumumab) •    A very small proportion (1.5%) of those fully vaccinated and treated with ofatumumab developed COVID-19. Despite being fully or partially vaccinated all patients with…

Data support body of evidence for ocrelizumab

Genentech, a member of the Roche Group, announced new Ocrevus® (ocrelizumab) data on 4th April 2022 that show its benefit on disease progression and cognitive outcomes in primary progressive multiple sclerosis (PPMS) and secondary progressive MS (SPMS). Separate analyses on treatment disparities among newly diagnosed patients with MS by race and ethnicity were presented at the…

Ublituximab trials in Multiple Sclerosis

 TG Therapeutics, Inc. announced data from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis (RMS) at the American Academy of Neurology (#AAN2022) annual meeting, 2-7 April 2022 in Washington, USA. Highlights of the presentations are outlined below. We are pleased to present additional analyses from…